However , zoledronic acid improved IDFS in those who were over 5 years since menopause at trial entry ( n = 1041 ; HR 077 , 95 % CI 063-096 ) but not in all other ( premenopause , perimenopause , and unknown status ) menopausal groups ( n = 2318 ; HR 103 , 95 % CI 089-120 ) .